Document is current
Any future updates will be listed below
-
Authors
Adler, Julia M. https://orcid.org/0000-0001-8147-0351
Martin Vidal, Ricardo https://orcid.org/0000-0002-9670-5640
Langner, Christine https://orcid.org/0000-0001-7311-3477
Vladimirova, Daria
Abdelgawad, Azza
Kunecova, Daniela
Lin, Xiaoyuan https://orcid.org/0000-0002-3361-0126
Nouailles, Geraldine https://orcid.org/0000-0003-1973-3119
Voss, Anne
Kunder, Sandra https://orcid.org/0000-0002-5023-8397
Gruber, Achim D. https://orcid.org/0000-0002-4502-0393
Wu, Haibo https://orcid.org/0000-0002-5961-2947
Osterrieder, Nikolaus
Kunec, Dusan
Trimpert, Jakob https://orcid.org/0000-0003-1616-0810
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB-TR84 Z01b)
RocketVax AG c/o Swiss Rockets AG Rittergasse 3, 4051 Basel Switzerland
- License Information
-
More Information
Article History
Received: 17 November 2023
Accepted: 17 January 2024
First Online: 2 February 2024
Competing interests
: Related to this work, Freie Universität Berlin has filed a patent application (PCT/EP2022/051215) for the use of sCPD9 and sCPD9-ΔFCS as vaccines. In this application, J.T., N.O., and D.K. are named as inventors of sCPD9. The patent application does not preclude the use of sCPD9 for scientific purposes. Freie Universität Berlin is collaborating with RocketVax Inc. for further development of sCPD9-ΔFCS as a vaccine and receives funding for research. The remaining authors declare no competing interests.
